UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
Reed Elsevier PLC ——————————————————————————————————— |
||||
| (Translation of registrant’s name into English) | ||||
|
1-3 Strand London WC2N 5JR |
||||
|
——————————————————————————————————— (Address of principal executive office) |
||||
|
Reed Elsevier NV ——————————————————————————————————— |
||||
| (Translation of registrant’s name into English) | ||||
| Radarweg 29 1043 NX Amsterdam PO Box 470 1000 AL Amsterdam | ||||
|
——————————————————————————————————— (Address of principal executive office) |
||||
| Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F | ||||
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] | ||||
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] | ||||
| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No | ||||
| If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a |
Director/PDMR Shareholding
| Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
| Reed Elsevier PLC | ||
| Date: 03/05/2014 | By: |
/s/A.McCulloch |
| Name: | A.McCulloch | |
| Title: | Deputy Secretary | |
| Reed Elsevier NV | ||
| Date: 03/05/2014 | By: |
/s/A.McCulloch |
| Name: | A.McCulloch | |
| Title: | Authorised Signatory | |
| Exhibit No. | Description | |
|
|
|
|
| 99 | Director/PDMR Shareholding 03/05/2014 | |
ISSUED ON BEHALF OF REED ELSEVIER PLC AND REED ELSEVIER NV
4 March 2014
Director/PDMR Shareholdings
Reed Elsevier announces that it today received notification of the following transactions in the securities of Reed Elsevier by Erik Engstrom, Director, and Ian Fraser and Henry Udow, PDMRs:
(a) Reed Elsevier Group plc Bonus Investment Plan 2010 (“BIP”)
Vesting of matching shares
In connection with the vesting on 28 February 2014 of the share awards granted in May 2011 under BIP, the table below shows the total numbers of shares which vested and the numbers of shares actually released to Erik Engstrom, Ian Fraser and Henry Udow after taking account of shares withheld to meet personal tax and national insurance obligations.
| No. of Reed | No. of Reed | No. of Reed | No. of Reed | |||||||||||||
| Elsevier PLC | Elsevier NV | Elsevier PLC | Elsevier NV | |||||||||||||
| ordinary | ordinary | ordinary | ordinary | |||||||||||||
| shares/ADRs* vested | shares/ADRs* vested | shares/ADRs* | shares/ADRs* | |||||||||||||
| released | released | |||||||||||||||
Director |
||||||||||||||||
Erik Engstrom |
55,364 | * | 29,342 | * | ||||||||||||
PDMR |
||||||||||||||||
Ian Fraser |
8,097 | 39,346 | 4,291 | 20,853 | ||||||||||||
Henry Udow |
37,758 | 20,011 | ||||||||||||||
| 9,224 | * | 4,888 | * | |||||||||||||
*Denotes vesting/release of ADRs. Each Reed Elsevier NV ADR represents 2 Reed Elsevier NV ordinary shares. Each Reed Elsevier PLC ADR represents 4 Reed Elsevier PLC ordinary shares.
The closing market price of each security on the date of vesting was £9.155 per Reed Elsevier PLC ordinary share, €15.88 per Reed Elsevier NV ordinary share, $61.48 per Reed Elsevier PLC ADR and $43.67 per Reed Elsevier NV ADR.
(b) Reed Elsevier Group plc Long Term Incentive Plan (“LTIP”)
Vesting of performance shares
In connection with the vesting on 28 February 2014 of the share awards granted in May 2011 under LTIP, the table below shows the total numbers of shares which vested and the numbers of shares actually released to Ian Fraser and Henry Udow after taking account of shares withheld to meet personal tax and national insurance obligations.
No. of Reed |
No. of Reed | No. of Reed | No. of Reed | |||||||||||||
Elsevier PLC |
Elsevier NV | Elsevier PLC | Elsevier NV | |||||||||||||
ordinary shares |
ordinary shares | ordinary shares | ordinary shares | |||||||||||||
vested |
vested | released | released | |||||||||||||
| PDMR | ||||||||||||||||
| Ian Fraser | 49,214 |
32,876 | 26,083 | 17,424 | ||||||||||||
| Henry Udow | 47,209 |
31,536 | 25,020 | 16,714 | ||||||||||||
The closing market price of each security on the date of vesting was £9.155 per Reed Elsevier PLC ordinary share and €15.88 per Reed Elsevier NV ordinary share.
(c) Reed Elsevier Group plc Executive Share Option Scheme (“ESOS”): Exercise of Options
The following options to acquire Reed Elsevier ordinary shares were exercised by Erik Engstrom on 4 March 2014.
Date of grant
|
Plan name | No. of Reed Elsevier PLC ordinary shares |
No. of Reed Elsevier NV ordinary shares |
Option price per share |
||||||||||
| Director | ||||||||||||||
| Erik Engstrom | 13 March 2006
|
ESOS | 178,895 | £5.305 | ||||||||||
13 March 2006
|
ESOS | 120,198 | €11.470 | |||||||||||
(d) Sale of shares
On 4 March 2014, Erik Engstrom and Ian Fraser sold the following securities set out below.
| No. of Reed Elsevier PLC ordinary shares/ADRs* sold |
Price per Reed Elsevier PLC ordinary shares/ADRs** |
No. of Reed Elsevier NV ordinary shares/ADRs* sold |
Price per Reed Elsevier NV ordinary shares/ADRs** |
|||||||||
Director
|
||||||||||||
Erik Engstrom
|
174,895 | £9.138158 | 119,198 | €15.7552 | ||||||||
| 28,342* | $43.3972** | |||||||||||
PDMR
|
||||||||||||
Ian Fraser
|
26,083 | £9.05 | 38,277 | €15.64 | ||||||||
*Denotes sale of ADRs. Each Reed Elsevier NV ADR represents 2 Reed Elsevier NV ordinary
shares.
** Denotes price per ADR
Following these transactions, the current interests of Erik Engstrom in the share capital of Reed Elsevier PLC and Reed Elsevier NV are:
Reed Elsevier PLC Reed Elsevier NV |
118,552 ordinary shares 516,765 ordinary shares |
- ENDS -
Enquiries
Paul Abrahams (Media)
+44 20 7166 5724
Colin Tennant (Investors)
+44 20 7166 5751